Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. In a March 26 research note, analyst Joseph Pantginis reported that IMV Inc.'s (IMV:TSX; IMMVD:OTCQX) preliminary monotherapy data confirmed the efficacy o...
Streetwise Reports | April 1, 2019 |

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease

Trial results for this therapeutic, and their implications for this biotech, were discussed in an H.C. Wainwright & Co. report. In an April 4 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Inovio Pharmaceuticals Inc.'s (INO:NASDA...
Streetwise Reports | April 11, 2019 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent

With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report. In a May 17 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed possible data readout scenarios of En...
Streetwise Reports | May 27, 2019 |

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. Early this morning, gene therapy focused biopharmaceutical company IVERIC bio Inc. (I...
Streetwise Reports | October 29, 2019 |

Why Did ImmunoGen Plummet 32%?

This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. ImmunoGen Inc.'s (IMGN:NASDAQ) shares closed down 32.06% on the NASDAQ Wednesday after announcing the United States ...
Streetwise Reports | May 21, 2019 |

PODCAST: A CBD-focused First-to-Market Franchise Model

This podcast is part of our Cannabis Sector CEO interview series. The focus of our new StockTalk Podcasts is to help listeners and investors learn about, understand, and discover investment opportunities in the public marketplace.   Stockhouse Media's Dave Jackson was r...
Dave Jackson | September 19, 2019 |

Research and Technology Company Builds off Great Results

CB2 Insights ( C.CBII , OTC:CBTOF , Forum ) launched as a public company in March 2019 and, against trend in the small cap space, operated with cash flows from operations while growing the company 24 percent year-on-year with Q3 revenues reaching $4.2M. Recently, ...
Dave Jackson | December 23, 2019 |
1 2 3 4 5 6 7 8 9 10 ...